The varying impurity profiles of mRNA from the IVT step calls on options in purification technologies that would allow process development scientists to mix and match media based on the specific characteristics of the molecule.
Share this article
Share this article
BOSTON, May 13, 2021 /PRNewswire/ The Boston R&D Center and GeneLeap Biotech, two subsidiaries of Luye Life Sciences Group, took part in the 24
th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, presenting the progress of four of the company s latest preclinical developments in gene and cell therapy to the global biological community.
ASGCT is one of the world s most influential academic conferences in the area of gene and cell therapy. More than 3,500 scholars, clinical investigators, physicians and other professionals attend the meeting every year. The ASCCT annual meeting is held as a virtual event from May 11 to 14 this year.
GeneLeap Announces Novel GalNAc Synthesis and Evaluation in Mice as Antisense Oligonucleotide Conjugates at ACS 2021
News provided by
Share this article
Share this article
BOSTON, April 25, 2021 /PRNewswire/ GeneLeap Biotech, a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an e-poster entitled
Design and synthesis of novel GalNAc linker moieties, conjugation to antisense oligonucleotides and evaluation in mice at the Spring Meeting of the American Chemical Society (ACS) 2021. The study reported new synthetic methodologies for the synthesis of novel tri-antennary GalNAc units and their evaluation for delivery and efficacy as GalNAc-antisense oligo conjugates in mice.
GeneLeap Announces Novel GalNAc Synthesis and Evaluation in Mice as Antisense Oligonucleotide Conjugates at ACS 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021
News provided by
Share this article
Share this article
BOSTON, April 14, 2021 /PRNewswire/ GeneLeap Bio., a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an ePoster entitled Hydrogel encapsulated TLR9 agonists show sustained tumor growth inhibition and prolong survival of CT26 tumor-bearing mice at the American Association for Cancer Research 2021 Annual Meeting. The preclinical study shows that compared with using TLR9 agonist on its own, a hydrogel encapsulated TLR9 agonist, independently developed by GeneLeap Biotech, can significantly improve antitumor performance, while demonstrating tumor growth inhibitory effects similar to that of TLR9 agonist without hydrogel encapsulation.